Carlisle, K., Kowalski, R., Hu-Bianco, Q. L., Dream, S. Y., Russell, J. O., Hodak, S. P., Kuo, J. H., & Hu, Y. (2025). Consensus Thyroid Nodule Radiofrequency Ablation Reporting Guidelines Established Using a Delphi Approach. Endocrine Practice. https://doi.org/10.1016/j.eprac.2025.06.006

Osinga, J. A. J., Liu, Y., Männistö, T., Vafeiadi, M., Tao, F.-B., Vaidya, B., Vrijkotte, T. G. M., Mosso, L., Bassols, J., López-Bermejo, A., Boucai, L., Aminorroaya, A., Feldt-Rasmussen, U., Hisada, A., Yoshinaga, J., Broeren, M. A. C., Itoh, S., Kishi, R., Ashoor, G., … Korevaar, T. I. M. (2024). Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis. Thyroid®, 34(5), 646–658. https://doi.org/10.1089/thy.2023.0646

Osinga, J. A. J., Derakhshan, A., Feldt-Rasmussen, U., Huang, K., Vrijkotte, T. G. M., Männistö, T., Bassols, J., López-Bermejo, A., Aminorroaya, A., Vafeiadi, M., Broeren, M. A. C., Palomaki, G. E., Ashoor, G., Chen, L., Lu, X., Taylor, P. N., Tao, F.-B., Brown, S. J., Sitoris, G., … Korevaar, T. I. M. (2023). TSH and FT4 Reference Interval Recommendations and Prevalence of Gestational Thyroid Dysfunction: Quantification of Current Diagnostic Approaches. The Journal of Clinical Endocrinology & Metabolism, 109(3), 868–878. https://doi.org/10.1210/clinem/dgad564

Rubin, M. R., Cusano, N., Yin, S., Tokareva, E., Ayodele, O., & Finkelman, R. D. (2024). Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic Hypoparathyroidism. Endocrine Practice, 30(3), 200–208. https://doi.org/10.1016/j.eprac.2023.12.001

Connelly, C. F., Cimic, A., & Baskota, S. (2023). Interpace, Affirma, and Thyroseq Performance Characteristics in 341 Bethesda Category III/IV Thyroid Nodules. American Journal of Clinical Pathology, 160(Supplement_1), S23–S24. https://doi.org/10.1093/ajcp/aqad150.051

Saber A, A., Morshed, A., Bangchen, W., Weining, Z., Chi, L., Apar Kishor, G., Vinicius, E., Alissa, M., Tony JC, W., Simon K, C., Michael, B., & Chi, Z. (2023). The Impacts of Angiotensin Receptor Blockers (ARBs) or Angiotensin-Converting Enzyme Inhibitors (ACEIs) on Patients with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage NSCLC. Journal of Radiology and Oncology, 7(2), 033–041. https://doi.org/10.29328/journal.jro.1001050